Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 291

Sort by

Sort Order Select

Journal Articles

Engineering CpG Deoxynucleotide-Conjugated Gold Nanoparticles for Enhanced Anti-Lymphoma Effects in an Immune Competent Lymphoma Model

Adam Yuh Lin, MD PhD, Jonathan Rink, PhD, Reem Karmali, MD, Colby Shad Thaxton, MD PhD, Leo I. Gordon, MD

Blood (2019) 134 (Supplement_1): 1577.

https://doi.org/10.1182/blood-2019-125308

Published: 2019

Journal Articles

Long-Term Follow-up of Follicular Lymphoma (FL) Patients (pts) Demonstrating Undetectable Minimal Residual Disease (MRD) Using a Next-Generation Based DNA Assay: Support for FL As a Curable Disease

Maryam Sarraf Yazdy, MD, Umair Jarral, MD, Chao Yin, MD, Frank Kuhr, PhD, Allison P. Jacob, Bruce D. Cheson, MD

Blood (2019) 134 (Supplement_1): 2813.

https://doi.org/10.1182/blood-2019-127262

Published: 2019

Journal Articles

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines

Gro Elise Rødland, PhD, Katrine Melhus, Roman Generalov, Sania Gilani, Francesco Bertoni, MD, Jostein Dahle, PhD, Randi Syljuåsen, PhD, Sebastian Patzke, PhD

Blood (2019) 134 (Supplement_1): 2574.

https://doi.org/10.1182/blood-2019-123287

Published: 2019

Journal Articles

Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study

Sameem Abedin, MD, Guru Subramanian Guru Murthy, MBBS, Lyndsey Runaas, MD, Laura C. Michaelis, MD, Ehab L. Atallah, MD, Mehdi Hamadani, MD, Alexandra M. Harrington, MDMT(ASCP), Karen Carlson, MD

Blood (2019) 134 (Supplement_1): 2605.

https://doi.org/10.1182/blood-2019-122487

Published: 2019

Journal Articles

PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001

Daniel O. Persky, MD, Hongli Li, MS, Deborah M. Stephens, DO, Steven I Park, MD, Nancy L. Bartlett, MD, Lode J. Swinnen, MB ChB, Paul M. Barr, MD, Jerome D. Winegarden, III, MD, Louis S. Constine, MD, Thomas J. Fitzgerald, MD, John P. Leonard, MD, Brad S. Kahl, MD, Michael L. Leblanc, PhD, Joo Y. Song, MD, Richard I. Fisher, MD, Lisa M. Rimsza, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2019) 134 (Supplement_1): 349.

https://doi.org/10.1182/blood-2019-123871

Published: 2019

Journal Articles

Radioimmunotherapy for Mantle Cell Lymphoma: 5-Year Follow-up of 90 Patients from the International RIT-Registry

Karin Hohloch, Christine Windemuth-Kieselbach, Pier Luigi Zinzani, MD PhD, Roberto E. Cacchione, MD, Wojciech Jurczak, MD PhD, Cheolwon Suh, Lorenz Truemper, MD, Christian W Scholz

Blood (2019) 134 (Supplement_1): 5263.

https://doi.org/10.1182/blood-2019-124192

Published: 2019

Journal Articles

Preclinical Development of an Actinium-225-Labeled Antibody Radio-Conjugate Directed Against CD45 for Targeted Conditioning and Radioimmunotherapy

Dale Ludwig, PhD BS, Ruth Bryan, Wojciech Dawicki, PhD, Eileen M Geoghegan, Qing Liang, PhD, Sandesh Seth, MS, MBA, Mamata Gokhale, Mark S. Berger, MD, Vijay Reddy, MD PhD, Ravendra Garg, Kevin Allen, PhD, Ekaterina Dadachova

Blood (2019) 134 (Supplement_1): 5601.

https://doi.org/10.1182/blood-2019-128678

Published: 2019

Journal Articles

Targeting CD45 with an Amanitin Antibody-Drug Conjugate Effectively Depletes Human HSCs and Immune Cells for Transplant Conditioning

Blood (2018) 132 (Supplement 1): 4526.

https://doi.org/10.1182/blood-2018-99-117167

Published: 2018

Journal Articles

Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody ( 90 Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS)

Phuong T. Vo, MD, Ted Gooley, PhD, Joseph G. Rajendran, MD, Darrell R. Fisher, PhD, Johnnie J. Orozco, MD PhD, Damian J. Green, MD, Ajay K. Gopal, MD, Robyn Haaf, BS, Margaret E. Nartea, BS, Rainer F. Storb, MD, Frederick R. Appelbaum, MD, Oliver W. Press, MD PhD, John M. Pagel, MD PhD, Brenda M. Sandmaier, MD

Blood (2018) 132 (Supplement 1): 1018.

https://doi.org/10.1182/blood-2018-99-111915

Published: 2018

Journal Articles

Cell Cycle Kinase Inhibitors Potentiate the Effect of 177 lu-Lilotomab Satetraxetan in Treatment of Aggressive Diffuse Large B-Cell Lymphoma Cell Lines

Gro Elise Rødland, PhD, Katrine Melhus, Jostein Dahle, PhD, Randi Syljuåsen, PhD, Sebastian Patzke, PhD

Blood (2018) 132 (Supplement 1): 1371.

https://doi.org/10.1182/blood-2018-99-110200

Published: 2018

Journal Articles

Modeling Targeted Lymphodepletion with Radiolabeled CD45 Antibody As a Promising Preparative Regimen Prior to Adoptive Cell Therapy or CAR-T

Dale L Ludwig, PhD BS, Mark S. Berger, MD, Dadachova Ekaterina, PhD, Kevin Allen, PhD, Wojciech Dawicki

Blood (2018) 132 (Supplement 1): 5682.

https://doi.org/10.1182/blood-2018-99-119740

Published: 2018

Journal Articles

The Alpha Emitter Astatine-211 Targeted to CD38 Can Eradicate Multiple Myeloma in Minimal Residual Disease Models

Shyril O'Steen, PhD, Melissa C. Comstock, BS, Johnnie J. Orozco, MD PhD, Donald K. Hamlin, BS, D. Scott Wilbur, PhD, Jon Jones, BS, Aimee Kenoyer, BS, Margaret E. Nartea, BS, Yukang Lin, PhD, Brian W. Miller, PhD, Sherilyn A. Tuazon, MD, Brian G. Till, MD, Ajay K. Gopal, MD, Brenda M. Sandmaier, MD, Oliver W. Press, MD PhD, Damian J. Green, MD

Blood (2018) 132 (Supplement 1): 1941.

https://doi.org/10.1182/blood-2018-99-119555

Published: 2018

Journal Articles

Speaking volumes about volumes

Bruce D. Cheson

Blood (2018) 131 (22): 2408–2409.

https://doi.org/10.1182/blood-2018-04-841924

Published: 2018

Journal Articles

CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies

Damian J. Green, Shyril O’Steen, Yukang Lin, Melissa L. Comstock, Aimee L. Kenoyer, Donald K. Hamlin, D. Scott Wilbur, Darrell R. Fisher, Margaret Nartea, Mark D. Hylarides, Ajay K. Gopal, Theodore A. Gooley, Johnnie J. Orozco, Brian G. Till, Kelly D. Orcutt, K. Dane Wittrup, Oliver W. Press

Blood (2018) 131 (6): 611–620.

https://doi.org/10.1182/blood-2017-09-807610

Published: 2018

Includes: Supplemental data

Journal Articles

Efficacy of 90Y-Ibritumomab Tiuxetan in the Older Population with Non-Hodgkin Lymphoma Pre-Treated with Rituximab-Based Regimens: A Single-Institution Experience

Vaibhav Agrawal, MD MBA, Smelser T. Diane, PhD, Jose I. Castillo, MD, Kelly Raup, RN, Girton D. Treanna, RN, Scotty R. Collins, MD, James O. Brady, MD, Sharif S. Khan, MD

Blood (2017) 130 (Supplement 1): 4066.

https://doi.org/10.1182/blood.V130.Suppl_1.4066.4066

Published: 2017

Journal Articles

Total Body Irradiation (TBI) Dose Escalation Decreases Risk of Progression and Graft Rejection after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning for Myelodysplastic Syndrome (MDS) or Myeloproliferative Neoplasms (MPN)

Federico Monaco, MD, Bart L. Scott, MD, Thomas Chauncey, MD PhD, Finn Petersen, MD, Barry E. Storer, PhD, Frederic Baron, Mary E. Flowers, MD, H. Joachim Deeg, MD, Rainer F. Storb, MD, David G. Maloney, MD PhD, Brenda M. Sandmaier, MD

Blood (2017) 130 (Supplement 1): 908.

https://doi.org/10.1182/blood.V130.Suppl_1.908.908

Published: 2017

Journal Articles

A Phase I Trial of 90 Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma

Sherilyn A Tuazon, MD, Brenda M. Sandmaier, MD, Johnnie J. Orozco, MD PhD, Ajay K. Gopal, MD, Leona A. Holmberg, MD PhD, Pamela S. Becker, MD PhD, Sally J. Lundberg, Brian G. Till, MD, Margaret E. Nartea, Ted Gooley, PhD, Darrell R. Fisher, PhD, Joseph G. Rajendran, MD, Oliver W. Press, MD PhD, William I. Bensinger, MD, Damian J. Green, MD

Blood (2017) 130 (Supplement 1): 910.

https://doi.org/10.1182/blood.V130.Suppl_1.910.910

Published: 2017

Journal Articles

Efficacy of Radiation Treatement in Ocular Adnexa Mucosa-Associated Lymphoid Tissue Lymphoma: A Retrospective Evaluation in a Single Center Experience

Dario Marino, MDPhD, Maital Bolshinsky, MD, Silvia Finotto, MD, Raffaele Parrozzani, MD, Caterina Boso, MD, Federica Vianello, MD, Edoardo Midena, MD, Luca Canziani, MD, Laura Evangelista, MD, Vittorina Zagonel, MD

Blood (2017) 130 (Supplement 1): 2781.

https://doi.org/10.1182/blood.V130.Suppl_1.2781.2781

Published: 2017

Journal Articles

Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS

Blood (2017) 130 (Supplement 1): 2048.

https://doi.org/10.1182/blood.V130.Suppl_1.2048.2048

Published: 2017

Journal Articles

A Phase II Trial Evaluating the Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed By Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkin's Lymphoma

Victor A. Chow, MD, Joseph Rajendren, MD, Andrew Shields, MD, Darrell R. Fisher, PhD, Frederick R. Appelbaum, MD, Ryan D. Cassaday, MD, Andrew J. Cowan, MD, Paul J. Martin, MD, Leona Holmberg, MD PhD, Ted Gooley, PhD, Philip A. Stevenson, MS, John M. Pagel, MD PhD, Damian J. Green, MD, Oliver W. Press, MD PhD, Ajay K. Gopal, MD

Blood (2017) 130 (Supplement 1): 2018.

https://doi.org/10.1182/blood.V130.Suppl_1.2018.2018

Published: 2017

NARROW

Engineering CpG Deoxynucleotide-Conjugated Gold Nanoparticles for Enhanced Anti-Lymphoma Effects in an Immune Competent Lymphoma Model

Long-Term Follow-up of Follicular Lymphoma (FL) Patients (pts) Demonstrating Undetectable Minimal Residual Disease (MRD) Using a Next-Generation Based DNA Assay: Support for FL As a Curable Disease

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines

Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study

PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001

Radioimmunotherapy for Mantle Cell Lymphoma: 5-Year Follow-up of 90 Patients from the International RIT-Registry

Preclinical Development of an Actinium-225-Labeled Antibody Radio-Conjugate Directed Against CD45 for Targeted Conditioning and Radioimmunotherapy

Targeting CD45 with an Amanitin Antibody-Drug Conjugate Effectively Depletes Human HSCs and Immune Cells for Transplant Conditioning

Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody ( 90 Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS)

Cell Cycle Kinase Inhibitors Potentiate the Effect of 177 lu-Lilotomab Satetraxetan in Treatment of Aggressive Diffuse Large B-Cell Lymphoma Cell Lines

Modeling Targeted Lymphodepletion with Radiolabeled CD45 Antibody As a Promising Preparative Regimen Prior to Adoptive Cell Therapy or CAR-T

The Alpha Emitter Astatine-211 Targeted to CD38 Can Eradicate Multiple Myeloma in Minimal Residual Disease Models

Speaking volumes about volumes

CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies

Efficacy of 90Y-Ibritumomab Tiuxetan in the Older Population with Non-Hodgkin Lymphoma Pre-Treated with Rituximab-Based Regimens: A Single-Institution Experience

Total Body Irradiation (TBI) Dose Escalation Decreases Risk of Progression and Graft Rejection after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning for Myelodysplastic Syndrome (MDS) or Myeloproliferative Neoplasms (MPN)

A Phase I Trial of 90 Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma

Efficacy of Radiation Treatement in Ocular Adnexa Mucosa-Associated Lymphoid Tissue Lymphoma: A Retrospective Evaluation in a Single Center Experience

Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS

A Phase II Trial Evaluating the Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed By Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkin's Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only